본문 바로가기
KERD
논문KCI 등재

갑상선암의 방사성요오드 치료에서 선량평가에 기반한 치료용량 결정의 방법과 임상적 유효성

Methods and Clinical Efficacy of Dosimetry-Based Treatment in Radioiodine Therapy of Thyroid Cancer

정준기|팽진철
대한갑상선학회 (Korean Thyroid Association)|2013.05|International Journal of Thyroidology|제6권 제1호|pp. 43-48

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

선량평가방사성요오드Dosimetry갑상선암RadioiodineThyroid cancer고정용량Fixed dose
주제분류의학일반

초록

Radioiodine (RI) therapy is one of the key factors for the good prognosis of differentiated thyroid cancers. Currently, most of RI treatments are performed with predetermined fixed dose of RI, whereas strict dose adjustment is made in chemotherapy or external radiotherapy for cancer treatment. Although fixed dose methods have been practically effective in RI therapy hitherto, dose determination with individual radiation dosimetry is theoretically superior to use of empirical fixed dose, for maximization of treatment effect and minimization of adverse events. The theoretical superiority of dosimetry-based dose determination is not yet directly supported by clinical data of real world; however, indirect results support the use of dosimetry-based dose determination in several specific patient groups. In this review, the basis of dosimetry is briefly discussed with regard to necessity and practical methods. Additionally, the efficacy of dosimetry is also discussed through the data of clinical studies so far.

Abstract

Radioiodine (RI) therapy is one of the key factors for the good prognosis of differentiated thyroid cancers. Currently, most of RI treatments are performed with predetermined fixed dose of RI, whereas strict dose adjustment is made in chemotherapy or external radiotherapy for cancer treatment. Although fixed dose methods have been practically effective in RI therapy hitherto, dose determination with individual radiation dosimetry is theoretically superior to use of empirical fixed dose, for maximization of treatment effect and minimization of adverse events. The theoretical superiority of dosimetry-based dose determination is not yet directly supported by clinical data of real world; however, indirect results support the use of dosimetry-based dose determination in several specific patient groups. In this review, the basis of dosimetry is briefly discussed with regard to necessity and practical methods. Additionally, the efficacy of dosimetry is also discussed through the data of clinical studies so far.

참고문헌 (38)

  1. Kyu-Won Jung, "Prediction of Cancer Incidence and Mortality in Korea, 2012", Cancer Research and Treatment, 44(1), pp.15~31 (2012), 대한암학회
  2. Van Nostrand D, "Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma", Thyroid, 12(2), pp.121~134 (2002)
  3. 이가희, "대한갑상선학회 갑상선결절 및 암 진료 권고안 개정안", Endocrinology and Metabolism, 25(4), pp.270~297 (2010), 대한내분비학회
  4. Maxon HR 3rd, "Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients", J Nucl Med, 33(6), pp.1132~1136 (1992)
  5. Maxon HR, "Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer", N Engl J Med, 309(16), pp.937~941 (1983)
  6. Benua RS, "The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer", Am J Roentgenol Radium Ther Nucl Med, 87, pp.171~182 (1962)
  7. Emami B, "Tolerance of normal tissue to therapeutic irradiation", Int J Radiat Oncol Biol Phys, 21(1), pp.109~122 (1991)
  8. Sgouros G, "Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule", J Nucl Med, 47(12), pp.1977~1984 (2006)
  9. Song H, "Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases", J Nucl Med, 47(12), pp.1985~1994 (2006)
  10. Hall P, "Cancer risks in thyroid cancer patients", Br J Cancer, 64(1), pp.159~163 (1991)
  11. Dottorini ME, "Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma", J Nucl Med, 36(1), pp.21~27 (1995)
  12. Ishikawa K, "Second primary neoplasms in thyroid cancer patients", Jpn J Cancer Res, 87(3), pp.232~239 (1996)
  13. Rubino C, "Second primary malignancies in thyroid cancer patients", Br J Cancer, 89(9), pp.1638~1644 (2003)
  14. Sawka AM, "Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis", Thyroid, 19(5), pp.451~457 (2009)
  15. Iyer NG, "Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy", Cancer, 117(19), pp.4439~4446 (2011)
  16. Wahl RL, "Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation", J Nucl Med, 39(8 Suppl), pp.14S~20S (1998)
  17. Furhang EE, "Thyroid cancer dosimetry using clearance fitting", J Nucl Med, 40(1), pp.131~136 (1999)
  18. Hermanska J, "Improved prediction of therapeutic absorbed doses of radioiodine in the treatment of thyroid carcinoma", J Nucl Med, 42(7), pp.1084~1090 (2001)
  19. Hänscheid H, "Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma", Endocr Relat Cancer, 16(4), pp.1283~1289 (2009)
  20. Freudenberg LS, "124-iodine positron emission tomography", computed tomography dosimetry in pediatric patients with differentiated thyroid cancer, 2007, pp.115(10), 690~693
  21. Freudenberg LS, "Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET", CT dosimetric comparisons, 2010, pp.37(12), 2267~2276
  22. Jentzen W, "The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(", CT) imaging, 2010, pp.37(12), 2298~2306
  23. Jentzen W, "Pre-therapeutic (124)I PET(", CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer, 2010, pp.37(5), 884~895
  24. Sgouros G, "Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer", Eur J Nucl Med Mol Imaging, 38(Suppl 1), pp.S41~S$& (2011)
  25. Van Nostrand D, "Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET", J Nucl Med, 53(3), pp.359~362 (2012)
  26. Lassmann M, "EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy", Eur J Nucl Med Mol Imaging, 35(7), pp.1405~1412 (2008)
  27. Freudenberg LS, "Clinical applications of 124I-PET", CT in patients with differentiated thyroid cancer, 2011, pp.38(Suppl 1), S48~S56
  28. Sgouros G, "Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software", J Nucl Med, 45(8), pp.1366~1372 (2004)
  29. Verburg FA, "The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients", Eur J Nucl Med Mol Imaging, 38(4), pp.673~680 (2011)
  30. Klubo-Gwiezdzinska J, "Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer", J Clin Endocrinol Metab, 96(10), pp.3217~3225 (2011)
  31. Kulkarni K, "The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer", Thyroid, 16(10), pp.1019~1023 (2006)
  32. Tuttle RM, "Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer", J Nucl Med, 47(10), pp.1587~1591 (2006)
  33. Dorn R, "Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach", J Nucl Med, 44(3), pp.451~456 (2003)
  34. Lee JJ, "Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma", Ann Nucl Med, 22(9), pp.727~734 (2008)
  35. Jentzen W, "Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer", Nucl Med Commun, 27(8), pp.669~676 (2006)
  36. Liu B, "Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial", J Nucl Med, 51(4), pp.618~623 (2010)
  37. Liu B, "Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer", Med Phys, 38(10), pp.5412~5419 (2011)
  38. Lassmann M, "Dosimetry and thyroid cancer: the individual dosage of radioiodine", Endocr Relat Cancer, 17(3), pp.R161~R172 (2010)

관련 논문AI추천

방사성요오드 치료: 경험적 고정용량투여방법에 대한 고찰과 선별적 응용박정미대한갑상선학회 · International Journal of Thyroidology2013 · 제6권 제1호저용량 대 고용량 방사성요오드 치료원경숙대한갑상선학회 · International Journal of Thyroidology2015 · 제8권 제1호갑상선암 전이의 방사성요오드 치료강건욱대한갑상선학회 · International Journal of Thyroidology2013 · 제6권 제1호분화갑상선암과 방사성요오드: 과거, 현재 그리고 미래조일, 이재태대한갑상선학회 · International Journal of Thyroidology2019 · 제12권 제2호방사성요오드 치료저항성 갑상선암에서 방사성요오드 병용치료의 새로운 전략오소원, 정준기, 팽진철대한갑상선학회 · International Journal of Thyroidology2015 · 제8권 제1호갑상선질환 환자의 방사성요오드 치료시 방사선 안전관리강성민, 김병일, 김인주, 범희승, 이가희, 이재태, 정웅윤, 정재훈대한갑상선학회 · International Journal of Thyroidology2012 · 제5권 제1호

이 간행물의 다른 논문 (11건)

갑상선기능항진증의 진단 및 치료- 대한갑상선학회 합의안이가희, 정재훈, 김인주, 송영기, 이재태, 문재훈, 정웅윤, 범희승pp. 1-11갑상선암 방사성요오드 치료에 관한 환자 안내서- 제 1 판(2012) -정재훈, 김원배, 김민희, 이용상, 이송미, 조영석, 정규환, 천기정, 김병일, 이규언, 석주원, 강성준, 박영주pp. 12-25영상을 이용한 방사핵종 치료의 선량평가임일한pp. 26-33방사성요오드 치료: 경험적 고정용량투여방법에 대한 고찰과 선별적 응용박정미pp. 34-42갑상선암 전이의 방사성요오드 치료강건욱pp. 49-55
원문 보기